#KLTO

Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026 Klotho Neurosciences (Nasdaq: KLTO) will rebrand as Greenland Mines Ltd and change its Nasdaq ticker to GRML effective at market open on March 12, 2026.The move follows the company's acquisition of Greenland Mines Corp. and control of the Skaergaard Project in Southeast Greenland, described as one of the world’s largest undeveloped palladium, gold and platinum deposits. No shareholder action is required; brokerage positions will update automatically. An investor webcast will be held March 12, 2026 at 4:15 PM ET to discuss the strategic rationale and shareholder benefits.

6 days ago

#KLTO Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

Klotho Neurosciences Announces Expiration of Letter of Intent Klotho Neurosciences (Nasdaq: KLTO) announced on October 7, 2025 that its Letter of Intent with Turn Biotechnologies was allowed to expire after evaluation by Klotho's board. The board concluded the proposed transaction did not match the company's long-term strategic plan. Klotho will instead concentrate resources on advancing its Klotho anti-aging protein research pipeline and developing treatments targeting longevity.The company cited the growing longevity medicine market and aging demographics as rationale for prioritizing its human Klotho protein programs.

5 months ago

#KLTO Klotho Neurosciences Announces Expiration of Letter of Intent

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership NEW YORK and PALO ALTO, Calif., Sept. 30, 2025/ PRNewswire/-- Klotho Neurosciences, Inc. today announced it has signed a Letter of Intent to acquire select assets from Turn Biotechnologies, Inc., a leader in induced pluripotent stem cells and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a...

5 months ago

#KLTO Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Klotho Neurosciences Shares Major Developments and Advances in Neurodegenerative Disease Market Klotho Neurosciences has marked significant milestones in neurodegenerative therapies. With new partnerships and funding, the company is poised for growth in this $8 billion market.

Klotho Neurosciences Shares Major Developments and Advances in Neurodegenerative Disease Market #United_States #New_York #Neurodegenerative #KLTO #Klotho

0 0 0 0

$8B Market Opportunity: Klotho Neurosciences Advances Revolutionary ALS Treatment with FDA Recognition Biotech firm secures FDA Orphan Drug Designation for KLTO-202 ALS therapy, raises $11M, and partners with AAVnerGene for manufacturing. Targets $8B neurodegenerative disease market.

6 months ago

#KLTO Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

6 months ago

NEWS: ( NASDAQ: #KLTO ) KLTO - Historical Earnings Price Analysis

0 0 0 0

6 months ago

BREAKING NEWS: ( NASDAQ: #KLTO ) KLTO - Historical Price Movements Surrounding Earnings

0 0 0 0

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology Klotho Neurosciences (NASDAQ:KLTO) has signed a binding agreement to manufacture its KLTO-202 gene therapy candidate using AAVnerGene's platform technology. The collaboration leverages AAVnerGene's innovative 'AAVone' platform and engineered HEK293 cell line for enhanced gene therapy production.The partnership aims to deliver several key advantages over traditional triple transfection methods, including higher titer concentration, fewer impurities, faster optimization, and reduced costs. Additionally, AAVnerGene's 'ATHENA' platform technology offers specific tissue-targeting capabilities, potentially providing safer alternatives to conventional AAV vectors that typically target the liver.

7 months ago

#KLTO Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology Klotho Neurosciences (NASDAQ: KLTO) announced plans to expand beyond its core neurology focus to evaluate the acquisition of complementary anti-aging technologies. The company aims to develop treatments targeting healthy brain function, organ health, and longevity indicators.Building on its existing programs KLTO-101 and KLTO-202 for neurodegenerative diseases, Klotho is exploring treatments related to the Klotho gene, which is linked to aging and longevity. The company's expanded focus includes targeting conditions such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia, and osteoporosis.The initiative involves assembling a scientific team to evaluate genes and proteins including alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin, with the goal of developing interventions to delay age-related diseases.

7 months ago

#KLTO UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

www.stocktitan.net/news/KLTO/updated-klotho...

0 0 0 0

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology Klotho Neurosciences (NASDAQ: KLTO) announced plans to expand beyond its core neurology focus to pursue technologies targeting muscle strength, bone health, and longevity indicators. The company is evaluating acquisitions of complementary technologies to support its proprietary anti-aging Klotho platform, while continuing the development of KLTO-101 and KLTO-202.The expansion focuses on addressing the decline of Klotho levels with age, which contributes to various age-related disorders including cardiometabolic disease, neurodegeneration, cancer, sarcopenia, and osteoporosis. The company is assembling a scientific team to evaluate genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin to develop interventions for age-related diseases.

7 months ago

#KLTO Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets Klotho Neurosciences (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc. to manufacture its gene therapy candidates using AAVnerGene's advanced AAV manufacturing and tissue-targeted delivery technologies.The collaboration aims to accelerate the development of KLTO's three key candidates: KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and motor neuron diseases, and KLTO-303 for aging-related pathologies. AAVnerGene's proprietary platforms - AAVone system and ATHENA platform - promise to deliver more cost-effective, faster manufacturing with higher efficacy, purity, and lower toxicity through improved tissue targeting.

7 months ago

#KLTO Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

Biotech Firm Klotho Neurosciences Overcomes NASDAQ Delisting Risk: Full Compliance Achieved Gene therapy company meets $1 minimum bid price and $2.5M equity requirements, ensuring continued NASDAQ listing. See compliance details and monitoring terms.

7 months ago

#KLTO Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease") Klotho Neurosciences (NASDAQ:KLTO) has received FDA Orphan Drug Designation for KLTO-202, its novel secreted-Klotho promoter gene therapy for treating Amyotrophic Lateral Sclerosis (ALS). This designation provides significant benefits including tax credits for clinical trials, GDUFA User Fee waivers, and 7 years of market exclusivity.KLTO-202 targets motor neuron diseases using a muscle-specific promoter called "desmin" to express the s-KL gene and protein, specifically delivering therapy to the neuromuscular junction. The company has completed proof of concept studies in two animal models and is initiating manufacturing while planning regulatory meetings with the FDA and EMA.

8 months ago

#KLTO Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

trending stonks

@trendingstocks.bsky.social

8 months ago

🚨 $KLTO 🚨

Why is Klotho Neurosciences, Inc. trending today? 🤔

#KLTO #stocks #stockmarket

0 0 0 0

8 months ago

Breaking News: ( NASDAQ: #KLTO ) Biotech Stock Rips Following Key Announcement

0 0 0 0

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS Klotho Neurosciences (NASDAQ: KLTO) announced advancement in manufacturing and process development for KLTO-202, its investigational gene therapy treatment for amyotrophic lateral sclerosis (ALS). The company has licensed a unique RNA splice variant of the human alpha-Klotho gene from the Autonomous University of Barcelona for developing advanced gene therapies.The company's research has demonstrated that overexpression of secreted alpha-Klotho (s-KL) using gene therapy has shown positive therapeutic outcomes in multiple animal studies, including mouse and non-human primate models. The timeline for development indicates approximately 8 months for manufacturing and 4-6 months for regulatory processes, with Phase I/II clinical trials expected to begin by Q3 2026.KLTO plans to collaborate with contract research organizations (CROs) to manage manufacturing and clinical trials, maintaining operational efficiency without significant staff expansion. The company aims to use an AAV vector to deliver the s-KL gene directly to motor neurons affected by ALS, a disease that typically leads to paralysis and death within 2-3 years of diagnosis.

8 months ago

#KLTO Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

www.stocktitan.net/news/KLTO/klotho-neurosc...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Klotho Neurosciences Secures Over $11 Million Funding, Eliminating All Debt and Meeting Nasdaq Equity Requirements Klotho Neurosciences has successfully raised over $11 million, cleared all debt, and is now compliant with Nasdaq's stockholders' equity criteria.

Klotho Neurosciences Secures Over $11 Million Funding, Eliminating All Debt and Meeting Nasdaq Equity Requirements #United_States #New_York #financing #Klotho_Neurosciences #KLTO

0 0 0 0

Klotho Neurosciences Secures $11M Through Warrants, Eliminates All Debt in Major Financial Turnaround Fresh capital injection strengthens Klotho's balance sheet as biotech firm clears debt and meets NASDAQ requirements. See detailed financial transformation.

8 months ago

#KLTO KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

www.stocktitan.net/news/KLTO/klotho-neurosc...

1 1 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Jun 11th - #IREN #RXRX #APLD #KLTO #IOVA #RIG #KZIA #NUVB #XTIA #VTAK #JBLU #CLSK #SEDG #RMR #QUBT #HIVE #NNE #MGNX #LEU #ESPR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jun 10th - #RXRX #NVTS #IOVA #RIG #QUBT #TDOC #SPCE #SEDG #RGTI #PLUG #NAK #TGB #MGNX #APLD #KLTO #AREB #EVGN #BORR #ESPR #BTCS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Jun 9th #LAES #EOSE #TGB #IBRX #CIFR #ELAB #RIG #SNPX #RXRX #WULF #IOVA #NVTS #IREN #PTON #TRMD #LEU #KLTO #ESPR #BMGL #APLD - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

@prismmarketview.bsky.social

9 months ago

NEWS: ( NASDAQ: #KLTO ) PRISM Mid-Day Movers: Biotech Longevity Hopes and Weight Loss Funding Drive Market Action

0 0 0 0

PRISM MarketView

9 months ago

PRISM Mid-Day Movers: Biotech Longevity Hopes and Weight Loss Funding Drive Market Action
#KlothoNeurosciences #KLTO Soars 568% on Longevity Gene Study
#ReShapeLifesciences #RSLS Tumbles 42% After Announcing $2.6M Offering
prismmarketview.com/prism-mid-da...

0 0 0 0

9 months ago

BREAKING NEWS: ( NASDAQ: #KLTO ) Klotho Neuroscience Unveils Groundbreaking Approach to Extend Lifespan by Reactivating the Silenced Alpha-Klotho Gene

0 0 0 0